Deucravacitinib in PG

Part of paid clinical trials in Lebanon, New Hampshire.

Sponsor
Dartmouth-Hitchcock Medical Center
Study ID
NCT05821374
Phase
EARLY_PHASE1
Status
Withdrawn

Conditions

  • Pyoderma Gangrenosum

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The main goal of this study is to see if the study drug called "Deucravacitinib" is safe and effective in treating people with pyoderma gangrenosum (PG).

Key Dates

Start date
Apr 29, 2024
Status verified
Jun 2025
Primary completion
Apr 29, 2024
Completion
Apr 29, 2024

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Deucravacitinib
    Participants to receive Deucravacitinib 6 mg tablets orally twice daily for 12 weeks.

Primary Outcome Measure

Change in Physician's Global Assessment (PGA) [ Time Frame: Baseline; Days 8, 15, 29, 57, and 85; Follow up Day 115 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Dartmouth-Hitchcock Medical CenterLebanonNew Hampshire03576-

Find similar trials in Lebanon, NH

By research site
Dartmouth-Hitchcock Medical Center· Lebanon, NH

Related Studies